Unique ID issued by UMIN | UMIN000025748 |
---|---|
Receipt number | R000029219 |
Scientific Title | A phase II study of a short bevacizumab infusion in patients with metastatic colorectal cancer. |
Date of disclosure of the study information | 2017/04/03 |
Last modified on | 2020/01/22 16:01:28 |
A phase II study of a short bevacizumab infusion in patients with metastatic colorectal cancer.
A phase II study of a short bevacizumab infusion
A phase II study of a short bevacizumab infusion in patients with metastatic colorectal cancer.
A phase II study of a short bevacizumab infusion
Japan |
unresectable metastatic/recurrent colorectal cancer
Gastroenterology | Hematology and clinical oncology | Gastrointestinal surgery |
Adult |
Malignancy
NO
We investigated the safety and efficacy of short bevacizumab infusion in patients with metastatic colorectal cancer.
Safety,Efficacy
Phase II
Progression free survival
The rate of infusion reaction
The rate of infusion reaction
The rate of bevacizumab-induced proteinuria and hypertension
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Bevacizumab was given over 30 min at the first time. If patients had no infusion reaction,the time was shortend to 10 min
Not applicable |
Not applicable |
Male and Female
1) Patients with histologically verified adenocarcinoma of the colon and rectum
2) Patients with Unresectable metastatic/recurrent colorectal cancer
3) Patents without a previous chemotherapy or radiation therapy
4) ECOG Performance status of 0-2
1) Serious complication (interstitial pneumonitis, pulmonary fibrosis, renal failure, liver failure, poorly-controlled diabetes, poorly-controlled hypertension)
2) Symptomatic or asymptomatic but treated heart disease
3) Active infection.
4) History of serious drug hypersensitivity or a history of drug allergy
5) Brain metastasis
6) Patients with perforated disease
7) Patients with thrombosis
8) Hemorrhagic diathesis, coagulation disorder
9) Pregnant or lactating woman
10) Not appropriate for the study at the physician's assessment
55
1st name | koichi |
Middle name | |
Last name | Taira |
Osaka City University Graduate School of Medicine
Dept of Gastroenterology
5458585
Asahimachi 1-4-3 Abeno-ku, Osaka
06-6645-3811
koichit@med.osaka-cu.ac.jp
1st name | koihi |
Middle name | |
Last name | Taira |
Osaka City University Graduate School of Medicine
Dept of Gastroenterology
5458585
Asahimachi 1-4-3 Abeno-ku, Osaka
06-6645-3811
koichit@med.osaka-cu.ac.jp
Dept of Gastroenterology Osaka City University Graduate School of Medicine
Dept of Gastroenterology Osaka City University Graduate School of Medicine
Self funding
Osaka City University Graduate School of Medicine
Asahimachi 1-4-3 Abeno-ku, Osaka
06-6645-3811
koichit@med.osaka-cu.ac.jp
NO
2017 | Year | 04 | Month | 03 | Day |
Unpublished
Preinitiation
2017 | Year | 03 | Month | 31 | Day |
2017 | Year | 04 | Month | 10 | Day |
2019 | Year | 03 | Month | 30 | Day |
2019 | Year | 03 | Month | 30 | Day |
2017 | Year | 01 | Month | 19 | Day |
2020 | Year | 01 | Month | 22 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029219
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |